- Home
- APPS vs LYEL Comparison
APPS vs LYEL Comparison
Compare APPS & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APPS | LYEL |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.0M | 490.1M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | APPS | LYEL |
|---|---|---|
| Price | $3.18 | $19.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $6.25 | ★ $27.25 |
| AVG Volume (30 Days) | ★ 2.0M | 92.8K |
| Earning Date | 02-03-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.61 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $103,569,000.00 | $36,000.00 |
| Revenue This Year | $15.60 | N/A |
| Revenue Next Year | $11.34 | $17,438.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 38.55 | N/A |
| 52 Week Low | $2.11 | $0.39 |
| 52 Week High | $8.28 | $45.00 |
Technical Indicators
Market Signals| Indicator | APPS | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 25.82 | 37.16 |
| Support Level | N/A | $15.82 |
| Resistance Level | $5.76 | $27.30 |
| Average True Range (ATR) | 0.19 | 2.22 |
| MACD | -0.05 | -0.42 |
| Stochastic Oscillator | 7.09 | 21.26 |
Price Performance
Historical ComparisonAbout APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.